Oral cancer chemoprevention: A review

1 Rhodus NL, Kerr AR, Patel K. Oral cancer: leukoplakia, premalignancy, and squamous cell carcinoma. Dent Clin North Am. 2014;58(2):315-40. Search in Google Scholar

2 Elango JK, Gangadharan P, Sumithra S, Kuriakose MA. Trends of head and neck cancers in urban and rural India. Asian Pac J Cancer Prev. 2006;7(1):108-12. Search in Google Scholar

3 Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. CA Cancer J Clin. 2008;58(2):71-96. Search in Google Scholar

4 De Vries N, van der Waal I, Snow GB. Multiple primary tumours in oral cancer. Int J Oral Maxillofac Surg 1986;15(1):85–7. Search in Google Scholar

5 Leon X, Quer M, Diez S, Orus C, Lopez-Pousa A, Burgues J. Second neoplasm in patients with head and neck cancer. Head Neck 1999;21(3):204–10. Search in Google Scholar

6 Lippman SM, Hawk ET. Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Res 2009;69(13):5269-84. Search in Google Scholar

7 Braakhuis BJ, Brakenhoff RH, Leemans CR. Second field tumors: a new opportunity for cancer prevention? Oncologist 2005;10(7):493-500. Search in Google Scholar

8 Kuriakose MA, Sharan R. Oral Cancer Prevention. Oral Maxillofac Surg Clin N Am. 2006;18(4):493–511. Search in Google Scholar

9 Hasina R, Lingen MW. Angiogenesis in Oral Cancer. J Dent Educ. 2001;65(11): 1282-90 Search in Google Scholar

10 Iype EM, Pandey M, Mathew A, Thomas G, Sebastian P, Nair MK. Oral cancer among patients under the age of 35 years. J Postgrad Med 2001;47(3):171. Search in Google Scholar

11 Dahlstrom KR, Little JA, Zafereo ME, Lung M, Wei Q, Sturgis EM. Squamous cell carcinoma of the head and neck in never smoker-never drinkers: a descriptive epidemiologic study. Head Neck 2008;30(1):75–84. Search in Google Scholar

12 Lucenteforte E, Garavello W, Bosetti C, La Vecchi C. Dietary factors and oral and pharyngeal cancer risk. Oral Oncol 2009;45(6):461–67. Search in Google Scholar

13 Lindsay C, Seikaly H, Biron VL. Epigenetics of oropharyngeal squamous cell carcinoma: opportunities for novel chemotherapeutic targets. Journal of otolaryngology - head & neck surgery. 2017;46(1):9-9. Search in Google Scholar

14 Govindarajan R, Siegel ER, Simmons DL, Lang NP. Thiazolidinedione (TZD) exposure and risk of squamous cell carcinoma of head and neck (SCCHN). 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25 (18_suppl):1511. Search in Google Scholar

15 Suvarna C, Chaitanya NC, Ameer S, Inamdar P, Alugubelli S, Bhagyanagar A. Chemopreventive agents in oral premalignancy: A medical management review. Journal of International Society of Preventive & Community Dentistry. 2020 Mar;10(2):127. Search in Google Scholar

16 Siemianowicz K, Likus W, Dorecka M, Wilk R, Dziubdziela W, Markowski J. Chemoprevention of Head and Neck Cancers: Does It Have Only One Face?. BioMed Res Int. 2018 Sep 25;2018. Search in Google Scholar

17 Nadeau C, Kerr AR. Evaluation and management of oral potentially malignant disorders. Dental Clinics. 2018 Jan 1;62(1):1-27. Search in Google Scholar

18 Piattelli A, Fioroni M, Santinelli A, Rubini C. bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study. Oral Oncol. 1999 May 1;35(3):314-20. Search in Google Scholar

19 Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res. 2009 Nov;2(11):931-41. Search in Google Scholar

20 Armstrong WB, Kennedy AR, Wan XS, Atiba J, McLaren CE, Meyskens FL. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Prev Biomarkers. 2000 Jan 1;9(1):43-7. Search in Google Scholar

21 Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, Le AD, Perloff M, Civantos F, Goodwin WJ, Wirth LJ. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prev Res. 2013 May;6(5):410-8. Search in Google Scholar

22 Mallery SR, Tong M, Shumway BS, Curran AE, Larsen PE, Ness GM, Kennedy KS, Blakey GH, Kushner GM, Vickers AM, Han B. Topical application of a mucoadhesive freeze-dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo-controlled clinical trial. Clin Cancer Res. 2014 Apr 1;20(7):1910-24. Search in Google Scholar

23 Epstein JB, Wong FL, Millner A, Le ND. Topical bleomycin treatment of oral leukoplakia: a randomized double-blind clinical trial. Head & neck. 1994 Nov;16(6):539-44. Search in Google Scholar

24 Mak MP, William Jr WN. Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention. Oral Oncol. 2014 Oct 1;50(10):918-23z. Search in Google Scholar

25 Galli A, Mello T, Ceni E, Surrenti E, Surrenti C. The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opin Investig Drugs. 2006 Sep 1;15(9):1039-49. Search in Google Scholar

26 Papadimitrakopoulou VA, William WN, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 2008;14(7):2095–101. Search in Google Scholar

27 Behura SS, Singh DK, Masthan KM, Babu NA, Sah S. Chemoprevention of oral cancer: A promising venture. Int J Oral Care Res. 2015;3(2):80-7. Search in Google Scholar

28 Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002;41(1):41 – 55. Search in Google Scholar

29 Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, et al. 13-cisretinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986; 315(24):1501–5. Search in Google Scholar

30 Papadimitrakopoulou VA, Clayman GL, Shin DM, Myers JN, Gillenwater AM, Goepfert H, et al. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 1999;125(10):1083–9. Search in Google Scholar

31 Shin DM, Khuri FR, Murphy B, Garden AS, Clayman G, Francisco M, et al. Combined interfereone alpha, 13-cis-retinoic acid, and alpha tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 2001; 19(2):3010–7. Search in Google Scholar

32 Mao L, Papadimitrakopoulou V, Shin DM, Fan Y, Zhou X, Lee JS, et al. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst. 1998; 90(20):1545–51. Search in Google Scholar

33 Nagao T, Warnakulasuriya S, Nakamura T, Kato S, Yamamoto K, Fukano H, et al. Treatment of oral leukoplakia with a low dose of beta-carotene and vitamin C supplements: A randomized controlled trial. Int J Cancer. 2015;136(7):1708-17. Search in Google Scholar

34 Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, Rudy S, et al. Randomized, double-blind, placebo controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res 2004; 10(5):1565–73. Search in Google Scholar

35 Normanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, De Luca A, et al. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 2005;6(3): 243–57. Search in Google Scholar

36 William WN, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY. Erlotinib and the Risk of oral cancer: the erlotinib prevention of oral cancer (EPOC) randomized clinical trial. JAMA Oncol 2016;2(2):209-16. Search in Google Scholar

37 Saba NF, Hurwitz SJ, Kono SA, Yang CS, Zhao Y, Chen Z, et al. Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase 1b and pharmacokinetic study. Cancer prev Res (Phila) 2014;7(3):283–91. Search in Google Scholar

38 Rudin CM, Cohen EE, Papadimitrakopoulou VA, Silverman S, Recant W, El-Naggar AK, et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 2003; 21(24): 4546–52. Search in Google Scholar

39 Li Y, Li LJ, Zhang ST, Wang LJ, Zhang Z, Gao N, et al. In vitro and clinical studies of gene therapy with recombinant human adenovirus-p53 injection for oral leukoplakia. Clin Cancer Res 2009;15(21):6724–31. Search in Google Scholar

40 Rhodus N, Rohrer M, Pambuccian S, Keel S, Bliss R, Szabo E. Phase IIa Chemoprevention Clinical Trial of Pioglitazone for Oral Leukoplakia. J Dent Res 2011; 90(A) [abstract]. Search in Google Scholar

41 Rosas RR, Nachbor KM, Handley N, Mathison G, Wuertz BR, Ba’th F, Ondrey FG. Preclinical evidence for pioglitazone and bexarotene combination in oral cancer chemoprevention. Head & neck. 2022 Mar;44(3):661-71. Search in Google Scholar

42 Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21(2895):e2900. Search in Google Scholar

43 Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009;2(11):931–41. Search in Google Scholar

44 Kerr AR, Lodi G. Management of oral potentially malignant disorders. Oral Diseases. 2021;27(8):2008-25. Search in Google Scholar

45 Saba NF, Haigentz M, Vermorken JB, Strojan P, Bossi P, Rinaldo A, et al. Prevention of head and neck squamous cell carcinoma: Removing the “chemo” from “chemoprevention”. Oral Oncol. 2015;51(2):112-18. Search in Google Scholar

46 Foy JP, Bertolus C, William WN Jr, Saintigny P. Oral premalignancy: the roles of early detection and chemoprevention. Otolaryngol Clin North Am. 2013;46(4):579-97. Search in Google Scholar

47 Nandini DB, Rao RS, Deepak BS, Reddy PB. Sulforaphane in broccoli: The green chemoprevention!! Role in cancer prevention and therapy. Journal of Oral and Maxillofacial Pathology: JOMFP. 2020;24(2):405. Search in Google Scholar

48 Nagini S, Letchoumy PV, Thangavelu A, Ramachandran CR. Humans and hamsters: A comparative evaluation of carcinogen activation, DNA damage, cell proliferation, apoptosis, invasion, and angiogenesis in oral cancer patients and hamster buccal pouch carcinomas. Oral Oncol 2009;45(6): e31-7 Search in Google Scholar

49 William WN, Papadimitrakopoulou VA. Optimizing biomarkers and endpoints in oral cancer chemoprevention trials Cancer Prev Res (Phila). 2013;6(5):375-8. Search in Google Scholar

50 Wu X, Desai KG, Mallery SR, Holpuch AS, Phelps MP, Schwendeman SP. Mucoadhesive fenretinide patches for site-specific chemoprevention of oral cancer: enhancement of oral mucosal permeation of fenretinide by coincorporation of propylene glycol and menthol. Mol Pharm. 2012;9(4):937-45. Search in Google Scholar

51 Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC. Advanced Drug Delivery Systems of Curcumin for Cancer Chemoprevention. Cancer Prev Res (Phila) 2011; 4(8):1158–71. Search in Google Scholar

52 Habibi N, Bissonnette C, Pei P, Wang D, Chang A, Raymond JE, Lahann J, Mallery SR. Mucopenetrating Janus Nanoparticles For Field-Coverage Oral Cancer Chemoprevention. Pharmaceutical Research. 2023;12:1-6. Search in Google Scholar

53 Martinez VD, MacAulay CE, Guillaud M, Lam WL, Zhang L, Corbett KK, et al. Targeting of chemoprevention to high-risk potentially malignant oral lesions: Challenges and opportunities. Oral Oncol. 2014;50(12):1123-30. Search in Google Scholar